Interview with Enrica Giorgetti, General Director, Farmindustria, Italy
Despite Italy being one of the most important pharmaceutical markets not only in Europe but also in the World, the industry remained quite stable for the last two years and…
At Astellas, a commitment to creating a brighter future is the foundation of everything we do.
Our vision is to change tomorrow. To improve the lives of men, women and children by providing innovative medicines in areas of health where there is urgent need for better treatments. Transplant recipients, patients fighting cancer, those with life-threatening infections – these are just some of the patients we are striving to help now and in the future through a single-minded focus on research and development in areas of high unmet medical need.
CHANGING TOMORROW™ is the ethos that guides everything that Astellas does, and is the measure by which we judge our success.
Contact
Astellas Pharma S.p.A.
P.I 00789580966 – C.F. 04754860155
L’indirizzo della Sede Astellas è:
Via del Bosco Rinnovato, 6 – Edificio U7
20090 Assago (MI)
Tel.: +39 02 921381
Despite Italy being one of the most important pharmaceutical markets not only in Europe but also in the World, the industry remained quite stable for the last two years and…
Grunenthal-Formenti relies on Formenti’s 60 years experience in Italy and is the result of the merger of both the German and Italian entities in 96. How would you describe the…
Having led a 26 years long career in Pfizer, you have been involved in a number of different countries including leading markets such as the US and Japan, but also…
You have worked in other countries such as the UK and the US with very large and significant pharmaceutical industries. What would you say is particular about the Italian pharmaceutical…
Since 1982, CNR has been the Italian public body which most contributed to the creation of inventions and innovations. What have been the main strategies behind such a success in…
Over more than 25 years, PAREXEL has expanded its global footprint through a combination of organic growth, alliances, and acquisitions. What was the rationale behind entering Italy in 1995 and…
Roche Italy is one of the companies which went through the most significant re-organization process in the country in the past three years- with important changes in both its marketing…
When you were appointed General Director of the Agenzia Italiana del Farmaco (AIFA) in 2007, the dedicated Investigation Commission highlighted the need for an in-depth reorganization of the Agency in…
“The ball is in the hands of the government,” according to Giorgio Foresti, general manager of Ratiopharm. “Once aware of the opportunities created by generics, politicians will have to make…
The pharmaceutical industry arose from science – and so did Italy’s knowledge based economy. Building on a reputation for innovation carved in the 15th century, when Leonardo Da Vinci, Michelangelo,…
Petrone group was created in 1965, based on your parents’ Carmine and Fernanda’s entrepreneurial spirit. They survived through times of challenges for Italian groups and maintained their independence. In your…
Scharper’s history in the Italian market begins in 1958, but the company as we see it today was really created in the mid nineties, when you founded La Farmochimica Italiana…
See our Cookie Privacy Policy Here
